Annual report [Section 13 and 15(d), not S-K Item 405]

SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES (Details)

v3.26.1
SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Revenues:    
Total revenues $ 5,820
Cost of sales 1,532
Royalties 1,893
Research and development costs:    
Non-cash stock-based compensation 10,779 6,628
Total research and development costs 26,812 34,360
Selling, general and administrative costs:    
Total selling, general and administrative costs 65,031 29,851
Other segment items, net [1] 160,631 477
Net income (loss) 71,183 (63,734)
Research and Development Expense [Member]    
Research and development costs:    
Salaries & related costs 10,247 15,345
Non-cash stock-based compensation 1,355 1,561
Other selling, general and administrative costs [2] 15,210 17,454
General and Administrative Expense [Member]    
Research and development costs:    
Salaries & related costs 24,978 10,729
Non-cash stock-based compensation 9,424 5,067
Other selling, general and administrative costs [3] 23,470 9,237
Selling, general and administrative costs:    
Commercial costs 7,159 4,818
Product [Member]    
Revenues:    
Total revenues 2,420
License [Member]    
Revenues:    
Total revenues $ 3,400
[1] Other segment items include interest income, interest expense, change in fair value of warrant and derivative liabilities, gain on sale of priority review voucher, other income, net and income tax (benefit) expense.
[2] Other research and development costs include, but are not limited to preclinical lab supplies, preclinical and development costs, clinical trial costs, preclinical manufacturing and manufacturing facility costs, costs associated with preclinical regulatory approvals, preclinical depreciation on lab supplies and manufacturing facilities, and preclinical consultant-related expenses.
[3] Other selling, general and administrative costs primarily consist of office facility costs, public reporting company related costs, professional fees (e.g., legal expenses), regulatory costs, production costs not attributable to cost of sales and other general operating expenses not otherwise included in research and development expenses.